title: Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
abstract: Peripheral metabolism of L-DOPA via enzyme catechol-O-methyltransferase (COMT) is one of the possible sources of homocysteine (HCY). The aim of this study was to assess plasma HCY levels in L-DOPA-treated Parkinson's disease (PD) patients and its influence by adding the inhibitor COMT (entacapone). Patients were divided into two groups: (1) patients long term treated with L-DOPA but were naïve to entacapone, (2) L-DOPA naïve patients, in whom a combined treatment with L-DOPA and entacapone was started. The HCY levels were higher in Group 1 than in Group 2. No statistically significant changes of HCY concentrations were found in both patient groups after adding entacapone to their L-DOPA treatments. Results of this study confirm that patients treated with L-DOPA for a long term have increased plasma HCY concentrations. We believe combined L-DOPA and entacapone therapy could be a possible protective mechanism against hyperhomocysteinemia in early PD.
authors.affiliation: Department of Neurology, University Hospital and Palacký University Medical School, I. P. Pavlova 6, 77520, Olomouc, Czech Republic. nevrly.martin@post.cz
authors.forename: Martin
authors.initials: M
authors.lastname: Nevrly
authors.forename: Petr
authors.initials: P
authors.lastname: Kanovsky
authors.forename: Hana
authors.initials: H
authors.lastname: Vranova
authors.forename: Katerina
authors.initials: K
authors.lastname: Langova
authors.forename: Petr
authors.initials: P
authors.lastname: Hlustik
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002396:Catechols / Q000627:therapeutic use*; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D002396:Catechols; D009570:Nitriles; D006710:Homocysteine; D007980:Levodopa; C071192:entacapone
references.citation: Nutr Rev. 2002 Dec;60(12):410-3
references.pmid: 12521146
references.citation: J Neural Transm Suppl. 1993;39:165-72
references.pmid: 8360656
references.citation: N Engl J Med. 1995 Feb 2;332(5):286-91
references.pmid: 7816063
references.citation: Am J Hum Genet. 1998 Nov;63(5):1541-3
references.pmid: 9792881
references.citation: Lancet. 1995 Nov 25;346(8987):1395-8
references.pmid: 7475822
references.citation: Parkinsonism Relat Disord. 2005 Mar;11(2):131-3
references.pmid: 15734674
references.citation: N Engl J Med. 2002 Feb 14;346(7):476-83
references.pmid: 11844848
references.citation: Acta Neurol Scand. 2003 Jul;108(1):66-7
references.pmid: 12807397
references.citation: Neurotoxicology. 1995 Fall;16(3):527-9
references.pmid: 8584284
references.citation: Clin Chem. 2001 Jun;47(6):1102-4
references.pmid: 11375298
references.citation: Arterioscler Thromb. 1991 Sep-Oct;11(5):1129-36
references.pmid: 1911700
references.citation: Lancet. 1999 Jul 10;354(9173):126-7
references.pmid: 10408491
references.citation: Eur Neurol. 1998 Nov;40(4):225-7
references.pmid: 9813406
references.citation: Acta Neuropathol. 2003 May;105(5):415-9
references.pmid: 12677440
references.citation: Annu Rev Nutr. 1999;19:217-46
references.pmid: 10448523
references.citation: Eur J Pediatr. 1998 Apr;157 Suppl 2:S40-4
references.pmid: 9587024
references.citation: Clin Chem Lab Med. 2003 Nov;41(11):1392-403
references.pmid: 14656016
references.citation: Parkinsonism Relat Disord. 2005 Jun;11(4):253-6
references.pmid: 15878587
references.citation: Mov Disord. 2004 Dec;19(12):1403-8
references.pmid: 15390053
references.citation: Eur J Neurol. 2005 May;12(5):365-8
references.pmid: 15804266
references.citation: Neurology. 2002 Dec 10;59(11):1708-13
references.pmid: 12473757
references.citation: Cardiovasc Drugs Ther. 2002 Sep;16(5):391-9
references.pmid: 12652108
references.citation: Neurology. 2000 Aug 8;55(3):437-40
references.pmid: 10932284
references.citation: Arch Neurol. 2003 Jan;60(1):59-64
references.pmid: 12533089
references.citation: Neurol Res. 2006 Dec;28(8):853-8
references.pmid: 17288745
references.citation: Neurology. 2003 Apr 8;60(7):1125-9
references.pmid: 12682318
references.citation: Lancet Neurol. 2003 Jul;2(7):425-8
references.pmid: 12849121
references.citation: Neurology. 2005 Apr 26;64(8):1482
references.pmid: 15851757
references.citation: N Engl J Med. 1998 Apr 9;338(15):1042-50
references.pmid: 9535670
references.citation: J Neurol Sci. 2003 Mar 15;207(1-2):19-23
references.pmid: 12614926
references.citation: Trends Neurosci. 2003 Mar;26(3):137-46
references.pmid: 12591216
references.citation: Clin Chem. 2004 Jan;50(1):3-32
references.pmid: 14709635
references.citation: J Nutr. 2000 Dec;130(12):3073-6
references.pmid: 11110872